Analysts forecast that Teligent, Inc. (NASDAQ:TLGT) will announce earnings per share (EPS) of $0.04 for the current quarter, according to Zacks. Three analysts have issued estimates for Teligent’s earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. The business is expected to announce its next quarterly earnings results on Thursday, October 26th.
According to Zacks, analysts expect that Teligent will report full year earnings of $0.14 per share for the current financial year, with EPS estimates ranging from $0.09 to $0.25. For the next financial year, analysts expect that the company will report earnings of $0.40 per share, with EPS estimates ranging from $0.24 to $0.56. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Teligent.
Teligent (NASDAQ:TLGT) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.04. The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $20.11 million. Teligent had a negative net margin of 14.35% and a positive return on equity of 5.43%. Teligent’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.02 earnings per share.
A number of research analysts have weighed in on TLGT shares. ValuEngine downgraded shares of Teligent from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. BidaskClub cut shares of Teligent from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Canaccord Genuity began coverage on shares of Teligent in a research note on Monday, July 31st. They set a “buy” rating and a $11.00 price objective for the company. Deutsche Bank AG reaffirmed a “hold” rating and set a $9.00 price objective (up previously from $8.00) on shares of Teligent in a research note on Monday, July 17th. Finally, Zacks Investment Research cut shares of Teligent from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $9.50.
Institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its position in Teligent by 19.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 48,030 shares of the company’s stock worth $375,000 after buying an additional 7,897 shares during the last quarter. Eagle Global Advisors LLC bought a new position in Teligent during the first quarter worth $309,000. Teza Capital Management LLC bought a new position in Teligent during the first quarter worth $116,000. UBS Asset Management Americas Inc. bought a new position in Teligent during the first quarter worth $170,000. Finally, Wells Fargo & Company MN boosted its position in Teligent by 3.1% in the first quarter. Wells Fargo & Company MN now owns 45,617 shares of the company’s stock worth $357,000 after buying an additional 1,369 shares during the last quarter. 62.75% of the stock is owned by hedge funds and other institutional investors.
Teligent (NASDAQ TLGT) opened at 6.77 on Thursday. The company’s market capitalization is $360.34 million. Teligent has a 12-month low of $5.75 and a 12-month high of $9.54. The stock’s 50 day moving average price is $8.45 and its 200 day moving average price is $8.02.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related stocks with our FREE daily email newsletter.